Marketresearchnews

Friday, 20 March 2020

DPT vaccine Market Research Report 2019 Analysis And Forecast To 2023

Globally the market for DPT vaccine is increasing rapidly. The major factor that derives the growth of DPT vaccine is the increasing deaths in children due to pertussis. Furthermore increasing awareness for DPT vaccines is increasing the growth of DPT vaccine market. Globally the market for DPT vaccine market is expected to grow at the rate of about XX% CAGR from 2016 to 2027.

Study Objectives of DPT vaccine Market:

To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the DPT vaccine market

To provide insights about factors affecting the market growth

To analyze the DPT vaccine market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

To provide country level analysis of the market with respect to the current market size and future prospective

To provide country level analysis of the market for segments by type, by applications and its sub-segments.

To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global

Key Players for DPT vaccine Market:

Some of the key players in this market are: Merck & Co., Inc (U.S), Sanofi (France), GSK (U.S), Lanzhou Institute of Biological Products (China), wyeth (U.S), Chiron Pharmaceutical Pvt Ltd (India) and many others.

Segments:
Global DPT vaccine market has been segmented on the basis of type which comprises of DPaT, DTwP and Tdap. On the basis of applications include diphtheria, pertussis and tetanus.

Regional Analysis of DPT vaccine Market:

Globally North America is the largest market for DPT vaccine. The North American market for DPT vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. This is due to increasing number of deaths of children in the country. Europe is the second-largest market for DPT vaccine which is expected to grow at a CAGR of XX%. Furthermore Asia pacific market is expected to be the growing market for DPT vaccine market.

The report for Global DPT vaccine Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the segments and regions of the different market.

About Us

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Biosimilars Market 2019 Analysis, Opportunities And Forecast To 2023

Biosimilars Market is expected to register a CAGR of 7.5% during the forecast period of 2019 to 2025, with a market value of USD 13,460 Million in 2018.

A biosimilar is a biologic medical product highly similar to another already approved biological medicine. Biosimilars are approved according to the same standards of pharmaceutical quality, safety, and efficacy that apply to all biological medicines. The global biosimilars market is driven by factors such as rising demand for biosimilars due to their cost-effectiveness and growing prevalence of chronic diseases. Additionally, rising pressure to reduce healthcare expenditure coupled with patent expiry of various blockbuster drugs and the increasing number of biosimilar drug approvals by the FDA is anticipated to fuel the market growth.

For instance, according to the biosimilars update report by Amgen in 2019, As of January 2019, the US Food and Drug Administration (FDA) approved 17 biosimilars, out of which 7 products launched in 4 therapeutic areas. On the other hand, patient safety and medical efficacy are projected to hamper the growth of the market during the assessment period. Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers to sustain their position in the market.

For instance, in October 2018, Sandoz, a Novartis division received the US Food and Drug Administration (FDA) approval for its biosimilar, HyrimozTM (adalimumab-adaz) for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PSA), juvenile idiopathic arthritis (JIA) in patients four years of age and older, ulcerative colitis (UC), ankylosing spondylitis (AS), adult Crohn's disease (CD), and plaque psoriasis (Ps)

Segmentation

The Global Biosimilars Market has been segmented based on product, applications, end users, and region.

The market, based on product, has been bifurcated into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides.

The recombinant non-glycosylated proteins are further divided into human growth hormone (RHGH), granulocyte colony-stimulating factor (filgrastim), insulin, and interferons. Similarly, the recombinant glycosylated proteins segment is further bifurcated into erythropoietin (EPO), monoclonal antibodies (MABS), and follitropin. The recombinant peptides segment has been subdivided into glucagon and calcitonin

The recombinant non-glycosylated proteins segment is expected to hold a major share in the market due to an increase in the number of incidences of chronic diseases, diabetes also growth hormone deficiency-related disorders. Thus, the therapeutic use of recombinant non-glycosylated proteins is broadening as their increased availability and lowered price.

For example, according to the International Diabetes Federation (IDF), in 2017, approximately 425 million adults aged between 20 to 79 years suffered from diabetes, and this number is expected to rise to 629 million by 2045.

On the basis of applications, the global biosimilars market has been divided into oncology, chronic diseases, autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others. Blood disorders segment is expected to grow with high growth rate due to increased prevalence of blood disorders and adoption of biosimilars as its low cost in comparison to biologics reduces the treatment cost.

For example, according to the Centers for Disease Control and Prevention in the US, hemophilia A affects 1 in 5,000 male births, and about 400 babies are born with hemophilia A each year.

Based on end user, the market has been divided into hospitals and clinics is expected to hold the largest share in the market as easy availability for treatment with expert faculties.

Based on region, the global biosimilars market has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The biosimilars market in the Americas has further been segmented into North America and Latin America; the North American market has been further divided into the US and Canada.

The European biosimilars market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as France, the UK, Germany, Italy, Spain, and the rest of Western Europe. The biosimilars market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The biosimilars market in the Middle East & Africa has been divided into the Middle East and Africa.

Key Players

The key players in the Global Biosimilars Market are Pfizer (US), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen, Inc. (US), Biocon (India), Dr. Reddy’s Laboratories (India), Celltrion (South Korea), Samsung Biologics (South Korea), Eli Lily & Company (US), Hospira Inc.(US), Actavis, Inc.(US), Cipla Ltd (India), Stada Arzneimittel AG (Germany), and Mylan, Inc.(US).

About Us

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Current And Forthcoming Erectile Dysfunction Drugs Market Size In Terms Of Volume And Value 2019

The global erectile dysfunction drugs market is expected to register a CAGR of ~3.5% during the forecast period of 2019 to 2025 with a market value of USD 2930 million in 2025.
Erectile dysfunction (ED) is defined as persistent difficulty achieving and maintaining an erection sufficient to have sex.
The global erectile dysfunction drugs market is driven by factors such as increasing number of men suffering from this disorder, rising geriatric population and patent expiry of number of blockbuster drugs.
Additionally, increasing manufactures of generic drugs coupled with rising adoption of a sedentary lifestyle along with the associated stress is anticipated to fuel the market growth.
For instance, according to The Massachusetts Male Aging Study (MMAS), worldwide incidence of erectile dysfunction will increase from 152 million men in 1995 to 322 million men by the year 2025.
On the other hand, poor patient adherence to erectile dysfunction drugs is projected to hamper the growth of the market during the assessment period.
Moreover, major companies in the market are involved in strategic acquisitions, collaborations, mergers, and new product launch to sustain their position in the market.
For instance, in December 2017, Teva Pharmaceutical Industries Ltd. announces exclusive launch of a generic version viagra tablets in the US.

Segmentation
The global erectile dysfunction drugs market has been segmented based on and region.
The market, based on drug, has been bifurcated into viagra (sildenafil citrate), cialis (tadalafil), staxyn/levitra (vardenafil), stendra/spedra (avanafil), zydena (udenafil), vitaros (alprostadil cream), and others. The market, on the basis of end user, has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Based on drug, viagra segment is expected to hold a major share in the market as it is the first Food and Drug Administration (FDA) approved oral treatment for erectile dysfunction. In 1998, Pfizer introduced viagra which is dominating the erectile dysfunction market. Cialis segment is expected to be the fastest growing segment as cialis provides an erection over a longer period than viagra, cialis lasts up to 18 hours, while viagra only lasts for about 4 to 6 hours.
On the basis of end user retail pharmacy segment is expected to be the largest segment as it is available easily in the retail stores. The hospital pharmacy segment is expected to be the fastest growing segment as increasing pool of patient due to increasing awareness and patient education.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The erectile dysfunction drugs market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European erectile dysfunction drugs market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The erectile dysfunction drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The erectile dysfunction drugs market in the Middle East & Africa has been divided into the Middle East and Africa.

Key Players
The key players in the global erectile dysfunction drugs market are Pfizer, Inc., Apricus Biosciences Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltd., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc., Teva Pharmaceutical Industries Ltd.

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Blood Glucose Test Strip MarkBlood Glucose Test Strip Market 2019 Market Challenge, Driver, Trends & Forecast To 2023

Blood glucose test strip is a small disposable plastic strip and is an important component of blood glucose meters that monitors and controls diabetes. These strips are impregnated with glucose oxidase, which reacts with glucose present in the blood and then indicate the glucose level in the blood.The convenience offered by the self-blood glucose testing over the traditional methods is one of the major drivers of the blood glucose test strip market. The self-testing allows the diabetic and the pre-diabetic people to keep a track of their blood glucose level regularly without visiting a clinic or diagnostic laboratory. A diabetic patient is expected to test his sugar at least 2-3 times a day, self-testing allows the patient to perform his test regularly at his home. Rising diabetic population is another major driver of the market. Diabetes is one of the major concerns for the government bodies across the globe. The number of diabetic population across the world is rising continuously. According to the International Diabetic Federation, about 415 million people had diabetes across the globe in 2015, and this number is poised to reach 642 million by 2040. Financial support by the governments is an important economic driver of the market due to its effects on the demand for blood glucose strips. For example, Australian Government is taking various initiatives to increase the usage of blood glucose monitors and test strips.

The government has implemented Pharmaceutical Benefits Scheme (PBS). According to this scheme, the blood glucose test strips are provided to the Australian at a government-subsidised prices. Moreover, the foreign visitors from the countries such as the U.K., Ireland, New Zealand, Malta, Italy, Sweden, the Netherlands, Finland, Norway, Belgium and Slovenia are also covered under this scheme. The other drivers for blood glucose test strips market are technological advancements such as accuracy of the test, awareness about diabetes, etc. Rising disposable income of emerging economies is another economic driver of the market. For example, annual disposable income of middle class households in India was $1,366.2 billion in 2010, which reached $1,587.6 billion in 2013.The market restraints are inadequate reimbursement for test strips etc. For example, in March 2013, Medicare announced reimbursement cuts for diabetes testing supplies (DTS) up to 72%. According to new reimbursement policies, diabetic beneficiaries, who receive their glucose-testing supplies delivered to their homes will need to obtain them from 1 of 18 contract suppliers chosen by Medicare via a competitive bidding process. This new plan will help the government to reduce healthcare expenditure. However, it can drastically reduce the number of vendors from which diabetic patients can obtain glucose-testing supplies. Furthermore, this amendment can also lead to disruption in the supplies of blood glucose monitoring accessories, which could result into decline in self-monitoring of glucose and subsequent adverse outcomes.The global big data in the blood glucose test strips market is expected to reach US$ 18.5 billion by 2020, and the market is projected to grow at a CAGR of ~ 6.2 % during the forecast period 2015-2020.

Segments
The global blood glucose test strip market has been segmented on the basis of technology. On the basis of technology the market has been segmented into thick film electrochemical, thin film electrochemical, and optical.

Regional analysis
The Americas holds a significant market share of the global market owing to extensive use of information technology and high expenditure on the health care. Additionally, the fastest uptake of new technology and the presence & concentration of medical device manufacturers in the US regions drive the blood glucose test strip market.North America led the global blood glucose test strip market with revenue of $ 7.89 billion in 2015.Europe is the second largest market in the globe due to a high healthcare expenditure, which is led by Germany and France.Asia Pacific region is expected to grow rapidly; China and India are likely to lead the market due to unmet needs during the forecasted period. APAC is expected to grow at a higher CAGR of 12.9 % than the other regions because of increasing number of diabetic population in this region.Gulf nations such as Saudi Arabia and the UAE drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic & political conditions and poor healthcare development.

Key Players in the Global Blood Glucose Test Strip Market
Some of key players profiled in the report are Abbott, Roche Diagnostics, LifeScan, i-SENS, Bayer Diabetes Care, AgaMatrix Inc, Elektronika, Universal Biosensors, Nipro Diagnostics, TaiDoc, Apex Biotechnology Corp, B. Braun, HMD BioMedical Inc., ALL Medicus, SANNUO, Beijing Yicheng Electronics, Betachek National Diagnostics, Shanghai MicroSense, Jiangsu Yuyue, ACON Laboratories and others.

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Clinical Nutrition Market 2019 Global– Key Players, Size, Trends, Growth- Analysis To 2023

Market Scenario

With the increasing aged population, the clinical nutrition spends are estimated to increase in the future. Due to the weak digestive framework at an old age, it becomes difficult for human body to digest all the required nutrients, rom food. Among aged population, the loss of appetite is considered a major issue; due to which, the elderly population does not get necessary amount of nutrients.

Therefore to get sufficient supplements, the confidence of the aged population towards clinical nutrition support, is growing. The global clinical nutrition market is going up because of high birth rate, raise in the number of victims receiving malnutrition treatment, and high number of premature births.

Study Objectives of Clinical Nutrition

To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Global Clinical Nutrition Market

To provide insights about factors affecting the market growth

To Analyze the Clinical Nutrition Market based on various factors- price analysis, supply chain analysis, porter’s five force analysis etc.

To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the World (ROW)

To provide country level analysis of the market with respect to the current market size and future prospective

To provide country level analysis of the market for segment by product types and their sub -segments

To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Clinical Nutrition Market

Key Findings

Asia-Pacific dominated the global clinical nutrition market in 2014; however it is expected to grow at a CAGR of XX% during 2016 – 2027.

The infant nutrition segment hold the largest share, with $XX billion value of the total market in 2014; while it is expected to reach $XX billion in 2027, at a CAGR of XX% for the period 2016-2027.

The milk-based infant nutrition segments hold the largest share, with $XX billion value, of the total market in 2014; while it is expected to reach $XX billion in 2027, at a CAGR of XX% for the period 2016 – 2027.

Key Players

The key players that are involved in Global Clinical Nutrition market are Baxter International, Inc, Abbott Laboratories, B. Braun Melsungen AG, Nestlé S.A, GroupeDanone, Mead Johnson Nutrition Company, Fresenius Kabi AG, Hospira, Inc, Perrigo Company Plc and among others.

Segments
Segmentation by Product

On the basis of product the market is segmented into:

Infant Nutrition (Milk Based, Soy Based, Organic, Others and Probiotic/Prebiotic)

Enteral Nutrition (Standard and For Chronic Illness)

Parenteral Nutrition

The report for Clinical Nutrition Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Wednesday, 18 March 2020

Neurostimulation Devices Industry Overview By Growth Factors, Product Chain Value, Competitors Analysis And Forecast 2023

Bioinformatics Market Information, by Application (genomics, chemoinformatics, drug design, transcriptomics, molecular phylogenetics, proteomics, metabolomics and others), by Technology and Services (data warehousing, sequence analysis, sequence manipulation and others), by Sector (medical bioinformatics, animal bioinformatics, agriculture bioinformatics and others) - Forecast to 2022

Market scenario:

The Global Bioinformatics Market is expected to exhibit a CAGR of 19.8% over the forecast period from 2016 to 2022, according to a new research report from Market Research Future (MRFR). The global bioinformatics trends and industry is mainly driven by the growing demand in developing countries in enhancing their healthcare sector and making advanced healthcare modalities available to patients.

The growing demand for electronic healthcare data storage is likely to be a major driver for the global bioinformatics market. The reliance on manual and paper-based documentation of healthcare procedures has resulted in unmanageable volumes of healthcare information, which can make it difficult to locate individual patients and their medical history. Electronic healthcare records, which are but the first step of the bioinformatics market, have already become widely popular in developed countries due to the benefits they present in terms of consistent data storage over the long term and ease in acquiring specific details at any given time. The growing demand for e-prescriptions and online pharmacies is likely to further the cause of the bioinformatics market over the forecast period, as strong bioinformatics networks are needed to operate and manage e-prescriptions and the related documentation.

The growing demand for strong data storage facilities in medical research is also likely to be a major driver for the global bioinformatics market. Bioinformatics plays a key role in genetic studies, in which it helps track details regarding multiple genes and their multifarious associations with the indicators being studied in the respective trial. The growing dependence on genetic studies in cancer research is likely to be a major driver for the global bioinformatics market over the forecast period, as cancer research has received strong government backing across the world. Other medical research applications are also likely to make use of bioinformatics systems on a large scale in the coming years, leading to steady growth of the global bioinformatics market over the forecast period.

Study Objectives of Bioinformatics Market:

To provide detail analysis of the market structure along with forecast for the next 7 years about various segments and sub-segments of the global bioinformatics market.
To provide insights about factors affecting the market growth.
To analyze the market based on price analysis, supply chain analysis, Porters Five Force analysis etc.
To provide past and estimated future revenue of the market’s segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
To provide country level analysis of the market with respect to the current market size and future growth prospective.
To provide country level analysis of the market for segments by drug application, by technology, by sector and services and its sub-segments.
To provide overview about key players and their strategic profiling in the market; comprehensively analyzing their core competencies and drawing a competitive landscape of the market.
To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Bioinformatics market.

Intended Audience

Bioinformatics service providers
Bioinformatics manufacturers
Research and development (R&D) companies
Government research laboratories
Government and independent regulatory authorities

Segmentation:

The global bioinformatics market is segmented on the basis of application, service, sector, and region in the MRFR report in order to provide a comprehensive coverage of all important factors related to the market’s growth prospects over the forecast period.

The bioinformatics market has been segmented on the basis of application into genomics, chemoinformatics, drug design, transcriptomics, molecular phylogenetics, proteomics, metabolomics, DNA sequences, and others. Increasing interest in genetic studies is likely to be a major driver for the global bioinformatics market over the forecast period.

On the basis of services and technology, the global bioinformatics market is segmented into data warehousing, sequence analysis, sequence manipulation, and others.

Key Players for Bioinformatics Market:

Agilent Technologies,
Illumina, Inc.,
QIAGEN N. V, and Thermo Fisher Scientific Inc.,
Dassault Systèmes,
QIAGEN and others.

Regional Analysis:

The global bioinformatics market is segmented by region into the Americas, Europe, Asia Pacific, and the Middle East and Africa. The global bioinformatics market is dominated by the Americas and Europe in terms of region due to the presence of strong telecommunications infrastructure in these regions to support advanced bioinformatics processes. The presence of a strong wireless internet and other telecommunication features is crucial for a bioinformatics system to function productively. This has actually been one of the key factors that has held back the bioinformatics market in underdeveloped regions.

In April 2019, researchers from UCLA announced a plan to develop a system that would allow scientists in developing countries to use cloud computing and big data analytics to accelerate the development of the bioinformatics field in their own countries. Efforts such as these are the result of the growing awareness of the disparity in terms of telecommunications infrastructure between developed and developing countries.

Asia Pacific is likely to exhibit the fastest growth over the forecast period due to the increasing efforts from governments in the region to incorporate powerful bioinformatics programs into the day-to-day functioning of their country’s healthcare sector.

Browse more Life Sciences Reports @ https://www.marketresearchfuture.com/categories/life-sciences-market-report

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Neurostimulation Devices Market Trend, Industry Overview, Competitive Analysis And Foreseen By 2023

Market Scenario:

Neurostimulation is a modulation of the nervous system’s activity. It is deliberately carried out by using invasive and non-invasive techniques. Implantable stimulation devices are most commonly used in the treatment of the neurological conditions such as epilepsy, Parkinson’s disease, dystonia, tremors, depression, obsessive compulsive disorder, diabetic neuropathy and few other conditions. Increasing cases of the neurological disorders such as chronic pain and depression high adoption of the Neurostimulation therapy are likely to improve the market of Neurostimulation devices. Globally, this Neurostimulation Devices Market Size is growing steadily and it is anticipated to show an exponential growth reaching approximately $11.5 billion in 2022

Segments:

Global Neurostimulation devices market has been segmented on the basis of type which comprises implantable devices, and external devices. Implantable devices include deep brain stimulators, spinal cord stimulators, sacral nerve stimulators, gastric electric stimulators, cochlear implants, and vagus nerve stimulators; whereas external devices include transcutaneous electrical nerve stimulator, and transcranial magnetic stimulator. On the basis of application, the market is segmented into dystonia, epilepsy, Parkinson's disease, depression, gastroparesis, pain management, tremors, urinary and fecal incontinence, and others. On the basis of end user, market is segmented into hospitals/clinics, cognitive care centers, research institutes and others.

Regional Analysis of Neurostimulation devices Market:

Considering the global scenario of the market, Americas region is believed to be the largest market for Neurostimulation devices. Moreover, the European market is also growing continuously and slowly catching up with the American market. On the other hand, Asia-Pacific market is expected to grow at the fastest pace in the Neurostimulation devices segment during the forecast period. Middle East & Africa region are likely to have a limited but steady growth in the market.

Key Players for Neurostimulation devices Market:

Some of the key players in this market are: Autonomic Technologies, Boston Scientific, ElectroCore, ImThera Medical, Inspire Medical Systems, LivaNova (Cyberonics), Medtronic, NeuroMetrix, NeuroPace, Neuros Medical, NeuroSigma, Nevro Corporation, SPR Therapeutics, St.Jude Medical, Synapse Biomedical, and others.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global Neurostimulation Devices market owing to the rising prevalence of the cardiovascular diseases such as cardiac arrhythmia, arterial blockage, and coronary artery disease among others. The development of the better therapeutic approaches and advanced treatment procedures have affected the growth of the American market in a positive way.

According to the data published by the Department of Health, New York in May 2018, percutaneous coronary intervention is one of the two most common procedures performed on patients with coronary artery disease. Besides this, the high medical awareness among American population, high disposable income, presence of the top medical device manufacturers in the region are some of the many factors that drive the growth of the Neurostimulation Devices market in this region.

Europe is expected to hold the second largest market share in the global Neurostimulation Devices market. The market growth in this region is majorly attributed to the increasing government support for the device manufacturers. Geographical expansion of companies has led to the wider reach of the medical products and services which has brought a huge change in terms of the acceptance and implementation of the new products as well as procedures. Similarly, Asia-Pacific region has observed a rapid growth in the Neurostimulation Devices market owing to the development in the medical sector in developing countries like India and China. Moreover, increase in government funding for healthcare, rising R&D expenditure, and growing number of medical device companies in the region has led to its fastest growth during the forecast period. The Middle East and Africa region is anticipated to show minor growth opportunities in the Neurostimulation Devices market during the forecast period.

Browse more Medical Devices Reports @ https://www.marketresearchfuture.com/categories/medical-devices-market-report

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com